Pulmokine, Inc.
Medtech
Quantitative phosphopeptide biomarker assay kit with stable isotopically labeled internal standards for pulmonary arterial hypertension diagnosis and prognosis via parallel reaction monitoring mass sp
pulmokine.net →- Grants
- $3.9M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 11
- 2 granted · 9 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension | $999,898 | |
| Federal grant | Department of Health and Human Services · Phase II · An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension | $5,000 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel inhaled c-kit/PDGFR inhibitor for the treatment of asthma | $337,324 | |
| Federal grant | Department of Health and Human Services · Phase II · An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension | $999,482 | |
| Federal grant | Department of Health and Human Services · Phase I · A phosphopeptide multiplex PRM mass spectroscopic biomarker assay for PAH | $515,573 | |
| Federal grant | Department of Health and Human Services · Phase II · An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension | $999,751 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1429 | Orcosa Inc. | — | $49M |
| 1430 | BH2 Innovations Inc. | — | $275K |
| 1431 | EKO Devices, Inc. | — | — |
| 1432 | Pulmokine, Inc. | — | — |
| 1433 | Piezobiomembrane, Inc. | — | — |
| 1434 | Unique Mobility Devices LLC | — | — |
| 1435 | Sigil, Inc. | — | $1.1M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Formulations Of Kinase Inhibitors And Prostanoidsapplication
- Combination Therapy For Treating Pulmonary Hypertensiongranted
- Formulations Of Kinase Inhibitors And Prostanoidsapplication
- Combination Therapy For Treating Pulmonary Hypertensiongranted
- Combination Therapy For Treating Pulmonary Hypertensionapplication
- Combination Therapy For Treating Pulmonary Hypertensionapplication
- Non-selective Kinase Inhibitorsapplication
- Non-selective Kinase Inhibitorsapplication
- Formulations Of Kinase Inhibitors And Prostanoidsapplication
- Combination Therapy For Treating Pulmonary Hypertensionapplication
- Formulations Of Kinase Inhibitors And Prostanoidsapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.